Urinary Bladder Carcinoma
Pipeline Programs↗
Active Trials↗
Companies Involved↗
Urinary Bladder Carcinoma is an emerging landscape with 22 programs across 16 companies. The most active players are Shanghai Pharmaceuticals Holding Co., Ltd, Coherus Oncology, Inc., EMD Serono. 11 therapies are approved with 2 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Analysis
Modality Breakdown
65%
Small molecule
15 of 23 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 23 classified programs, each share of the total. Modality classified for 100% of 23 pipeline programs.
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)